← All trials
NCT04969861
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Aug 31, 2025
- Completion date
- May 31, 2026
- First posted
- Jul 21, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nektar TherapeuticsLead sponsor
- MerckCollaborator
- Nektar TherapeuticsStudy director
- SFJ Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.